Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria

• •Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
• •Patients may be of either sex. Female patients must be non-lactating and must either be at least one year post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period
• •Patients must range in age from 18 to 75 years, inclusive.
• •Patients with type 2 diabetes must be drug naïve, receiving monotherapy with metformin or with a sulfonylurea, or combination therapy with both: metformin \& sulfonylurea.
• •Patients must have the following laboratory values:
• •* Hematocrit ≥ 34 vol%
• •* Serum creatinine ≤ 1.8 mg/dl
• •* AST (SGOT) ≤ 2.5 times upper limit of normal
• •* ALT (SGPT) ≤ 2.5 times upper limit of normal
• •* Alkaline phosphatase ≤ 2 times upper limit of normal
• •Patients must have been on a stable dose of allowed chronic medications for 30 days prior to entering the study.
• •Only subjects whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included.